Leishmania treatment and prevention: Natural and synthesized drugs

被引：79
作者：
Bekhit, Adnan A. [1 ,2 ]
El-Agroudy, Eman [1 ]
Helmy, Aliaa [3 ]
Ibrahim, Tamer M. [4 ]
Shavandi, Amin [5 ,6 ]
Bekhit, Alaa El-Din A. [7 ]
机构：
[1] Alexandria Univ, Dept Pharmaceut Chem, Fac Pharm, Alexandria 21521, Egypt
[2] Univ Bahrain, Coll Hlth Sci, Allied Hlth Dept, Pharm Program, POB 32038, Zallaq, Bahrain
[3] Alexandria Univ, Fac Pharm, Alexandria 21521, Egypt
[4] Kafrelsheikh Univ, Dept Pharmaceut Chem, Fac Pharm, Kafr Al Sheikh 33516, Egypt
[5] Univ Otago, Ctr Mat Sci & Technol, Dunedin, New Zealand
[6] Univ Libre Bruxelles, Interfac Sch Bioengineers, Brussels, Belgium
[7] Univ Otago, Dept Food Sci, Dunedin, New Zealand
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2018年 / 160卷
关键词：
Leishmaniasis; Herbal agents; Synthesized agents; Antileishmanial targets; Vaccination trials; VITRO ANTILEISHMANIAL ACTIVITY; AZAR DERMAL LEISHMANIASIS; IN-VITRO; VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; DNA CLEAVAGE; ARTEMISININ DERIVATIVES; MUCOSAL LEISHMANIASIS; QUINOLINE ALKALOIDS; TOPOISOMERASE-I;
D O I：
10.1016/j.ejmech.2018.10.022
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Leishmaniasis affects over 150 million people all over the world, especially in subtropical regions. Currently used antileishmanial synthesized drugs are associated with some drawbacks such as resistance and cytotoxicity, which hamper the chances of treatment. Furthermore, effective leishmanial vaccines are not well developed. Promising chemotherapy, either from natural or synthetic compounds, was or still is the most promising treatment. This review focuses on recent findings in drugs used for the treatment of leishmaniasis including; chemical and natural antileishmanial moieties, different potential targets, as well as various trials of vaccination development. Special emphasis has been paid to the mechanisms of the drugs, their safety and where possible, the structure-activity relationship to enable guided future drug discovery. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：229 / 244
页数：16
相关论文
共 198 条
[31]   Fluorescent Leishmania species: Development of stable GFP expression and its application for in vitro and in vivo studies [J].
Bolhassani, Azam ;
Taheri, Tahereh ;
Taslimi, Yasaman ;
Zamanilui, Soheila ;
Zahedifard, Farnaz ;
Seyed, Negar ;
Torkashvand, Fatemeh ;
Vaziri, Behrouz ;
Rafati, Sima .
EXPERIMENTAL PARASITOLOGY, 2011, 127 (03) :637-645
[32]   Synthesis and in vitro Evaluation of New Benzenesulfonamides as Antileishmanial Agents [J].
Borges, Julio C. ;
Carvalho, Adriana V. ;
Bernardino, Alice M. R. ;
Oliveira, Cesar D. ;
Pinheiro, Luiz C. S. ;
Marra, Roberta K. F. ;
Castro, Helena C. ;
Wardell, Solange M. S. V. ;
Wardell, James L. ;
Amaral, Veronica F. ;
Canto-Cavalheiro, Marilene M. ;
Leon, Leonor L. ;
Genestra, Marcelo .
JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY, 2014, 25 (05) :980-986
[33]   A Novel Leishmania major Amastigote Assay in 96-Well Format for Rapid Drug Screening and Its Use for Discovery and Evaluation of a New Class of Leishmanicidal Quinolinium Salts [J].
Bringmann, Gerhard ;
Thomale, Katja ;
Bischof, Sebastian ;
Schneider, Christoph ;
Schultheis, Martina ;
Schwarz, Tobias ;
Moll, Heidrun ;
Schurigt, Uta .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) :3003-3011
[34]   Analysis of iron superoxide dismutase-encoding DNA vaccine on the evolution of the Leishmania amazonensis experimental infection [J].
Campos, B. L. S. ;
Silva, T. N. ;
Ribeiro, S. P. ;
Carvalho, K. I. L. ;
Kallas, E. G. ;
Laurenti, M. D. ;
Passero, L. F. D. .
PARASITE IMMUNOLOGY, 2015, 37 (08) :407-416
[35]   Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation [J].
Carrion, Javier ;
Folgueira, Cristina ;
Soto, Manuel ;
Fresno, Manuel ;
Requena, Jose M. .
PARASITES & VECTORS, 2011, 4
[36]   Effect of LACK and KMP11 on IFN-γ production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients [J].
Carvalho, LP ;
Passos, S ;
Dutra, WO ;
Soto, M ;
Alonso, C ;
Gollob, KJ ;
Carvalho, EM ;
de Jesus, AR .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2005, 61 (04) :337-342
[37]   CHARACTERIZATION OF THE CELLULAR IMMUNE-RESPONSE IN AMERICAN CUTANEOUS LEISHMANIASIS [J].
CASTES, M ;
AGNELLI, A ;
VERDE, O ;
RONDON, AJ .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1983, 27 (02) :176-186
[38]   Evaluation of Antileishmanial Activity of Selected Brazilian Plants and Identification of the Active Principles [J].
Cechinel Filho, Valdir ;
Meyre-Silva, Christiane ;
Niero, Rivaldo ;
Bolda Mariano, Luisa Nathalia ;
do Nascimento, Fabiana Gomes ;
Farias, Ingrid Vicente ;
Gazoni, Vanessa Fatima ;
Silva, Bruna dos Santos ;
Gimenez, Alberto ;
Gutierrez-Yapu, David ;
Salamanca, Efrain ;
Malheiros, Angela .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
[39]   A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis [J].
Chakravarty, Jaya ;
Kumar, Subodh ;
Trivedi, Sonali ;
Rai, Vijay K. ;
Singh, Anup ;
Ashman, Jill A. ;
Laughlin, Elsa M. ;
Coler, Rhea N. ;
Kahn, Stuart J. ;
Beckmann, Anna Marie ;
Cowgill, Karen D. ;
Reed, Steven G. ;
Sundar, Shyam ;
Piazza, Franco M. .
VACCINE, 2011, 29 (19) :3531-3537
[40]   Exploring the inhibitory activity of Withaferin-A against Pteridine reductase-1 of L. donovani [J].
Chandrasekaran, Sambamurthy ;
Veronica, Jalaja ;
Gundampati, Ravi Kumar ;
Sundar, Shyam ;
Maurya, Radheshyam .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2016, 31 (06) :1029-1037
12345678910